|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash Flows From Operating Activities | |||||
| Net Income Loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities | |||||
| Depreciation | |||||
| Stock-based compensation expense | |||||
| Stock issuance for services | |||||
| Changes in operating assets and liabilities: | |||||
| Prepaid expenses and other current assets | |||||
| Inventory | |||||
| Accounts payable and accrued expenses | |||||
| Net cash used in operating activities | |||||
| Cash Flows From Investing Activities | |||||
| Purchase of property and equipment | |||||
| Purchase of short-term investments | |||||
| Maturities of short-term investments | |||||
| Net cash used in investing activities | |||||
| Cash Flows From Financing Activities | |||||
| Proceeds from sale of equity in IPO, net | |||||
| At The Market Offering | |||||
| Proceeds from sale of common stock, net of issuance costs | |||||
| Public Stock Offering | |||||
| At The Market Offering | |||||
| Total proceeds from sale of common stock, net of issuance costs | |||||
| Proceeds from exercise of stock options | |||||
| Proceeds from exercise of warrants | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash and restricted cash | |||||
| Cash, cash equivalents and restricted cash - beginning of the year | |||||
| Cash, cash equivalents and restricted cash - at end of the year | |||||
| Supplemental Disclosures of Cash Flow Information: | |||||
| Purchase of property and equipment in accounts payable | |||||
| Taxes paid | |||||
| Interest paid | |||||
| Issuance of common stock and warrants to settle accrued expenses | |||||
| Reconciliation of cash, cash equivalents and restricted cash: | |||||
| Cash and cash equivalents | |||||
| Restricted cash (included in other assets) | |||||
Loading...